GKIM
SUPN icon

GW&K Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

GW&K Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.2M Sell
1,037,242
-17,942
-2% -$862K 0.38% 92
2026
Q1 		$54.5M Sell
1,055,184
-25,532
-2% -$1.3M 0.48% 63
2025
Q4 		$53.7M Buy
1,080,716
+178
+0% +$8.65K 0.46% 71
2025
Q3 		$51.6M Sell
1,080,538
-184,268
-15% -$7.42M 0.46% 69
2025
Q2 		$39.9M Sell
1,264,806
-117,635
-9% -$3.77M 0.36% 106
2025
Q1 		$45.3M Buy
1,382,441
+176,091
+15% +$6.24M 0.42% 85
2024
Q4 		$43.6M Sell
1,206,350
-31,665
-3% -$1.11M 0.37% 106
2024
Q3 		$38.6M Sell
1,238,015
-55,300
-4% -$1.73M 0.33% 124
2024
Q2 		$34.6M Sell
1,293,315
-46,127
-3% -$1.34M 0.32% 130
2024
Q1 		$45.7M Buy
1,339,442
+21,916
+2% +$653K 0.4% 99
2023
Q4 		$38.1M Sell
1,317,526
-88,632
-6% -$2.35M 0.36% 118
2023
Q3 		$38.8M Buy
1,406,158
+6,903
+0.5% +$210K 0.39% 103
2023
Q2 		$42.1M Sell
1,399,255
-16,849
-1% -$590K 0.4% 100
2023
Q1 		$51.3M Buy
1,416,104
+9,576
+0.7% +$368K 0.5% 83
2022
Q4 		$50.2M Sell
1,406,528
-360,961
-20% -$12.5M 0.51% 74
2022
Q3 		$59.8M Sell
1,767,489
-142,360
-7% -$4.63M 0.66% 36
2022
Q2 		$55.2M Buy
1,909,849
+82,758
+5% +$2.37M 0.6% 51
2022
Q1 		$59.1M Sell
1,827,091
-9,375
-0.5% -$287K 0.53% 62
2021
Q4 		$53.6M Buy
1,836,466
+210,976
+13% +$6.4M 0.45% 88
2021
Q3 		$43.4M Buy
1,625,490
+9,390
+0.6% +$252K 0.39% 107
2021
Q2 		$49.8M Buy
1,616,100
+42,689
+3% +$1.31M 0.43% 83
2021
Q1 		$41.2M Buy
1,573,411
+256,071
+19% +$7.16M 0.38% 115
2020
Q4 		$33.1M Buy
1,317,340
+267,452
+25% +$5.76M 0.35% 133
2020
Q3 		$21.9M Buy
1,049,888
+259,087
+33% +$5.88M 0.29% 149
2020
Q2 		$18.8M Buy
+790,801
New +$17.5M 0.26% 166

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

GW&K Investment Management's SUPN Position: Q2 2026 in Review

GW&K Investment Management reduced its Supernus Pharmaceuticals (SUPN) stake by 1.7% in Q2 2026, selling an estimated $862K and leaving 1,037,242 shares worth $48.2M. The position accounts for 0.38% of the portfolio, ranked #92.

GW&K Investment Management first reported a position in SUPN in Q2 2020 and has held it in 25 quarters since. The position peaked at $59.8M in Q3 2022. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • GW&K Investment Management held 1,037,242 shares of Supernus Pharmaceuticals worth $48.2M as of Q2 2026.
  • GW&K Investment Management sold 17,942 Supernus Pharmaceuticals shares in Q2 2026, an estimated $862K.
  • Supernus Pharmaceuticals made up 0.38% of GW&K Investment Management's portfolio in Q2 2026, its #92 holding.
  • GW&K Investment Management first reported a position in Supernus Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • GW&K Investment Management's Supernus Pharmaceuticals position peaked at $59.8M in Q3 2022.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.